Pharsight

Verdeso patents expiration

VERDESO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492384 ALMIRALL Microemulsion and sub-micron emulsion process and compositions
Aug, 2025

(1 year, 11 months from now)

US8962000 ALMIRALL Microemulsion and sub-micron emulsion process and compositions
Aug, 2025

(1 year, 11 months from now)

US8460641 ALMIRALL Microemulsion process and composition
Aug, 2027

(3 years from now)

Verdeso is owned by Almirall.

Verdeso contains Desonide.

Verdeso has a total of 3 drug patents out of which 0 drug patents have expired.

Verdeso was authorised for market use on 19 September, 2006.

Verdeso is available in aerosol, foam;topical dosage forms.

Verdeso can be used as treatment of atopic dermatitis.

The generics of Verdeso are possible to be released after 13 August, 2027.

Drugs and Companies using DESONIDE ingredient

Market Authorisation Date: 19 September, 2006

Treatment: Treatment of atopic dermatitis

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage

VERDESO family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic